IRONDisc Medicine, Inc.

Healthcare
$62.08+2.1% 1Y

The financials

Disc Medicine, Inc. by the numbers

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Disc Medicine, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$65M−$61Mn/a
Net income−$60M−$55Mn/a
Diluted EPS−$1.54−$1.58n/a
On our screens:Most shorted stocks

Biotechnology

Ranks #108 of 196 by RyuScore

Compare peers
KLRA+16%
Kailera Therapeutics, Inc.
CLDX+2.1%
Celldex Therapeutics, Inc.
TARS+1.2%
Tarsus Pharmaceuticals, Inc.
TRVI+3.0%
Trevi Therapeutics, Inc.
RARE+1.4%
Ultragenyx Pharmaceutical Inc.
VERA+0.44%
Vera Therapeutics, Inc.